Alzheimer's disease is the No.
1 cause of death in the US between the ages of 75 and 94, according to the Alzheimer's Association, but there's no treatment currently on the market.
That could soon change.
Cognition Therapeutics, a clinical-stage biopharmaceutical company focused on the treatment of age-related degenerative disorders, announced Tuesday that CEO Lisa Ricciardi will present at two upcoming conferences, one at the Longwood Healthcare Leaders Spring MIT Conference on June 8 at 8:50am, and one at the Mass General Brigham World Medical Innovation Forum on June 12 at 3:30pm, per a press release.
In her presentation, Ricciardi will focus on " Emerging Modalities and Mechanisms for Treating CNS Diseases," which the company believes "represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases," per the press release.
The company's lead candidate is CT1812, a small molecule that specifically targets the ? '2 receptor, which is believed to regulate pathways that are impaired in Alzheimer's, dementia with Lewy bodies, and dry age-related macular degeneration, per the press release.
A customized collection of grant news from foundations and the federal government from around the Web.
Philanthropic organizations and housing associations could scale their impact and further their social missions by supporting social innovation of other individuals and groups.